A Devastating Double Bottom

Jan 6

Those who follow me know I love looking ahead to spot opportunities that are coming.

The AI revolution will create many losers and a few winners.
Some winning companies were obvious from the start, like Palantir in software and the entire chain of hardware manufacturers and infrastructure providers.

In my opinion, there’s now another sector about to surprise us… BIOTECH.

The ability to analyze millions (or billions) of molecular combinations will give an incredible boost to the search for new drugs and compounds.
AI is revolutionizing biotech in three key areas:

- accelerated drug discovery,
- protein modeling and predictive analysis,
- large-scale biological dataset analysis.

I’ve selected one of the most promising companies (more will follow).

The price has formed a double bottom, and the massive increase in volume confirms we’re at the bottom.
The POC around $4.90 is the first point of interest, located near the resistance area highlighted by the orange rectangle.

Breaking the neckline at $7 would push the price to retest the previous high around $12.

Jan 7

Note

Breakout, price on POC

Jan 16

Note

This idea was very well received, so I’ll go deeper into why I chose it.
Recursion is not a traditional biotech company: it’s a TechBio, and its supercomputer is the core of the entire business model. This is not just about “computing power,” but about an infrastructure designed to process biology at industrial scale.

Below are the key points.
⚙️ 1. One of the most powerful supercomputers in the biotech sector
Recursion has built a High‑Performance Computing (HPC) infrastructure that ranks among the most powerful supercomputers in the world.
It is designed to:

-process millions of cellular images every week
-train deep‑learning models on massive biological datasets
-simulate molecular and cellular interactions at scale

This enables Recursion to do in days what many biotech companies take months or years to achieve.
🧬 2. A massive proprietary biological dataset
A supercomputer is useless on its own—it needs fuel, and Recursion has plenty of it.
The platform generates:

-millions of automated biological experiments
-ultra‑high‑resolution cellular images
-unique chemical and phenotypic data

All of this is continuously processed by the supercomputer, creating a virtuous cycle:
more data → better models → new drug candidates → even more data.
This represents a huge barrier to entry for competitors.
🤝 3. NVIDIA’s investment is no coincidence
NVIDIA invested directly in Recursion for two main reasons:

-the sheer volume of biological data being generated
-Recursion’s ability to leverage GPUs and AI models at massive scale

Recursion uses NVIDIA’s stack (CUDA, DGX, etc.) to accelerate:

-phenotypic analysis
-virtual screening
-target and molecule prediction
-biological simulations

It is one of the very few biotech companies worldwide with AI infrastructure comparable to that of big tech.
🔄 4. Full automation: industrialized biology
The supercomputer is integrated with:

-laboratory robotics
-automated imaging systems
-machine‑learning pipelines
-high‑throughput screening platforms

This allows Recursion to:

test thousands of compounds in parallel
generate data 24/7
rapidly iterate between experiments and AI models

It’s a highly scalable approach—something extremely rare in the pharmaceutical sector.
🚀 5. Direct impact on company value
The supercomputer enables Recursion to:

-identify drug candidates faster
-reduce R&D costs
-increase the probability of clinical success
-attract partnerships (Bayer, Roche, NVIDIA, etc.)

In an industry where each year of development costs hundreds of millions, speed is a massive competitive advantage.
📌 In summary
Recursion’s supercomputer is not a “tech gadget,” but:

a digital biology factory
that combines data, automation, and AI to accelerate drug discovery.

It is likely the main reason why RXRX is considered one of the most promising TechBio companies.

Jan 22

Trade active

Breakout!
size increased, next target 7$

Feb 18

Note

Novo Nordisk has closed its position in Recursion, and the market did not like this news.
The stock may open with a -10% drop and move to test the purple support level.

Feb 18

Note

Someone got fleeced today.
It was the usual kind of news meant only to scare small investors and push them to sell their shares at the bottom, which are then immediately scooped up by the funds.
The price opened at –12%, and now it’s already at –2%… it might even close in the green